Practical Approach to Achieving 4 mg Daily Prednisolone Dose
Use an alternate-day dosing schedule with 5 mg and 2.5 mg tablets to achieve an average daily dose of approximately 4 mg when 4 mg tablets are unavailable. This approach is supported by guideline recommendations for glucocorticoid tapering in rheumatic diseases and is commonly used in clinical practice 1.
Recommended Dosing Strategies
Option 1: Alternate-Day Regimen (Preferred)
- Alternate 5 mg and 2.5 mg daily (e.g., 5 mg on Monday/Wednesday/Friday/Sunday, 2.5 mg on Tuesday/Thursday/Saturday)
- This provides an average of 3.75 mg per day, which is clinically equivalent to 4 mg
- The EULAR/ACR polymyalgia rheumatica guidelines specifically mention this approach: "1.25 mg decrements using schedules such as 10/7.5 mg alternate days" 1
Option 2: Weekly Pattern
- 5 mg for 4 days per week, 2.5 mg for 3 days per week
- Average daily dose: 4.1 mg
- Provides slightly more consistent dosing if the patient prefers a weekly routine
Option 3: Tablet Splitting (Less Preferred)
If 2.5 mg tablets are unavailable, you could split 5 mg tablets:
- One 5 mg tablet split in half daily provides approximately 2.5 mg per half
- However, research shows that splitting prednisolone tablets has accuracy within ±15% for halves 2
- This introduces dosing variability and should only be used if commercial 2.5 mg tablets are unavailable
Clinical Context for This Patient
Your patient with stable rheumatoid arthritis on leflunomide is in an ideal situation for this tapering approach:
- Leflunomide provides stable background disease control 3, allowing for gradual glucocorticoid reduction
- The 2014 EULAR RA guidelines emphasize that glucocorticoids should be tapered as rapidly as clinically feasible when combined with DMARDs 4
- The 2021 ACR guidelines strongly recommend initiating csDMARDs without longer-term (≥3 months) glucocorticoids 5
Important Considerations
Monitoring During Taper
- Assess disease activity every 4-8 weeks during this low-dose taper 4, 6
- Watch for flare symptoms: increased joint pain, morning stiffness, or swelling
- Recent evidence suggests that tapering to doses ≤2.5 mg/day carries higher flare risk (adjusted OR 1.37) compared to doses >2.5 mg/day 7
Adrenal Insufficiency Risk
- At doses below 5 mg daily, consider adrenal axis suppression, especially if the patient has been on glucocorticoids long-term 8
- If the patient experiences fatigue, weakness, or hypotension during tapering, test morning cortisol or perform ACTH stimulation testing before attributing symptoms to disease flare 8
Tapering Speed
- From 5 mg to 4 mg represents a 20% dose reduction
- Maintain the 4 mg equivalent dose for at least 4-8 weeks before further tapering 1
- The polymyalgia rheumatica guidelines recommend "1 mg every 4 weeks" for tapering below 10 mg daily 1
Next Steps After Achieving 4 mg
Once stable at 4 mg equivalent for 4-8 weeks:
- Taper to 2.5 mg daily (single tablet)
- Maintain for another 4-8 weeks if stable
- Consider 1.25 mg daily using alternate-day dosing (2.5 mg alternating with 0 mg) before complete discontinuation
- Do not rush the final taper below 5 mg - this is where both disease flares and adrenal insufficiency are most likely 7, 8
Common Pitfall to Avoid
Do not attempt to compound or crush tablets into suspensions unless absolutely necessary. While pharmacy-compounded suspensions provide better accuracy (±10%) 2, they require specialized preparation and are unnecessary for this straightforward dose adjustment. The alternate-day regimen using commercially available tablets is simpler, more reliable, and guideline-supported.